| 童陆媛,童照威.索磷布韦、达拉他韦联合或不联合利巴韦林对基因1b型慢性丙肝患者HCVRNA转阴率的影响[J].浙江中西医结合杂志,2019,29(9): |
| 索磷布韦、达拉他韦联合或不联合利巴韦林对基因1b型慢性丙肝患者HCVRNA转阴率的影响 |
| Effect of sofosbuvir, dalatavir and ribavirin on HCV RNA negative rate in chronic hepatitis C patients with gene 1b |
| 投稿时间：2018-11-02 修订日期：2019-07-02 |
| DOI： |
| 中文关键词: 慢性丙型肝炎 丙型肝炎病毒 利巴韦林 达拉他韦 索磷布韦 转阴 |
| 英文关键词:Chronic hepatitis C Hepatitis C virus Ribavirin Dalatavir Sofosbuvir Turn negative |
| 基金项目: |
|
| 摘要点击次数: 880 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 分析索磷布韦、达拉他韦联合或不联合利巴韦林对基因1b型慢性丙型肝炎(CHC)患者丙型肝炎病毒(HCV)-RNA(HCV RNA)转阴率的影响。方法 将本院收治的82例基因1b型CHC患者作为研究对象,根据患者治疗方法的不同,分为A组(36例)给予达拉他韦+索磷布韦+利巴韦林治疗,B组(46例)给予达拉他韦+索磷布韦治疗。比较两组患者治疗后HCV RNA转阴率,治疗结束后第4、12周HCV RNA不可测(SVR4、SVR12)及不良反应发生情况等差异。结果 在治疗4、8周时,两组患者HCV RNA转阴率有所增加；但治疗后12周时,两组患者HCV RNA转阴率并未继续升高,与治疗后8周时的转阴率持平。结果显示,两组患者在治疗4、8、12周时HCV RNA转阴率的比较,均无显著性差异(P>0.05)。两组患者SVR4、SVR12的比较,亦无显著性差异(P>0.05)。A组治疗期间出现贫血、皮疹、头痛、疲劳、恶心及心悸等不良反应发生率较B组明显升高(P<0.05)。结论 达拉他韦、索磷布韦联合或不联合利巴韦林对基因1b型CHC患者的临床疗效相当,均具有较高的HCV RNA转阴率,但联合利巴韦林可能存在不良反应增加的风险,且达拉他韦+索磷布韦联合治疗基因1b型CHC患者可尝试将疗程缩短为8周。 |
| 英文摘要: |
| ABSTRACT Objective To analyze the effect of sofosbuvir, dalatavir and ribavirin on the negative rate of hepatitis C virus (HCV) RNA (HCV RNA) in patients with genotype 1b chronic hepatitis C (CHC). Methods 82 patients with genotype 1b CHC were divided into group A (36 cases) treated with sofosbuvir + dalatavir + ribavirin and group B (46 cases) treated with sofosbuvir + dalatavir according to different treatment methods. The negative rate of HCV RNA, the unpredictability of HCV RNA (SVR4, SVR12) and the occurrence of adverse reactions were compared between the two groups. Results After 4 and 8 weeks of treatment, the negative rate of HCV RNA in both groups increased, but at 12 weeks after treatment, the negative rate of HCV RNA in both groups did not continue to increase, which was the same as that at 8 weeks after treatment. The results showed that there was no significant difference in the negative rate of HCV RNA between the two groups at 4, 8 and 12 weeks of treatment (P > 0.05). There was no significant difference in SVR4 and SVR12 between the two groups (P > 0.05). The incidence of anemia, rash, headache, fatigue, nausea and palpitation in group A was significantly higher than that in group B (P < 0.05). Conclusion The clinical efficacy of dalatavir, sofosbuvir combined with or without ribavirin in the treatment of genotype 1b CHC is comparable, and both of them have high negative rate of HCV RNA. However, the risk of increased adverse reactions may exist in the combination of dalatavir and sophobovir. In addition, the combination of dalartamivir and sophobovir can reduce the course of treatment to 8 weeks in patients with genotype 1b CHC. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
